Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy

After responding to highly active antiretroviral therapy (HAART), HIV-infected children had a good response to hepatitis B immunization. However, there are limited data on the durability of antibody to hepatitis B surface antigen (anti-HBs) in these children. The primary objective of this study is t...

Full description

Saved in:
Bibliographic Details
Main Authors: Mongkol Lao-araya, Thanyawee Puthanakit, Linda Aurpibul, Sineenart Taecharoenkul, Thira Sirisanthana, Virat Sirisanthana
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955646064&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/49720
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-49720
record_format dspace
spelling th-cmuir.6653943832-497202018-09-04T04:31:23Z Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy Mongkol Lao-araya Thanyawee Puthanakit Linda Aurpibul Sineenart Taecharoenkul Thira Sirisanthana Virat Sirisanthana Biochemistry, Genetics and Molecular Biology Immunology and Microbiology Medicine Veterinary After responding to highly active antiretroviral therapy (HAART), HIV-infected children had a good response to hepatitis B immunization. However, there are limited data on the durability of antibody to hepatitis B surface antigen (anti-HBs) in these children. The primary objective of this study is to determine the prevalence of protective anti-HBs level 3 years after a 3-dose HBV revaccination among HIV-infected children with immune recovery (CD4 cell ≥15%) while on HAART. The secondary objective is to assess immunologic memory among children who had waning of anti-HBs. An anti-HBs level of ≥10mIU/mL was defined as a protective antibody level. Sixty-nine HIV-infected children who had history of a 3-dose HBV revaccination while receiving HAART were enrolled. The mean (SD) of CD4 cell and duration of HAART at time of revaccination was 27.2% (6.7) and 5.9 years (0.4), respectively. The proportion of children with protective anti-HBs level 3 years after the revaccination was 71.0% [95% CI, 58.8-81.3]. The geometric mean titer was 114(SD 5)IU/mL. By multivariate logistic analysis, the predictors for protective anti-HBs level 3 years after revaccination were CD4 cell count ≥500cells/mm3at the time of vaccination (p=0.04) and anti-HBs level ≥100IU/mL at 1 month after completion of the 3-dose vaccination (p<0.001). Anamnestic response after one booster dose was demonstrated among 14 of 17 children who had waning protective anti-HBs level (82.4% [95% CI, 62.2-102.6]). Our findings support the recommendation of giving a 3-dose HBV vaccination to HIV-infected children with immune recovery while receiving HAART. © 2011 Elsevier Ltd. 2018-09-04T04:06:08Z 2018-09-04T04:06:08Z 2011-05-23 Journal 0264410X 2-s2.0-79955646064 10.1016/j.vaccine.2011.03.077 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955646064&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/49720
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Biochemistry, Genetics and Molecular Biology
Immunology and Microbiology
Medicine
Veterinary
spellingShingle Biochemistry, Genetics and Molecular Biology
Immunology and Microbiology
Medicine
Veterinary
Mongkol Lao-araya
Thanyawee Puthanakit
Linda Aurpibul
Sineenart Taecharoenkul
Thira Sirisanthana
Virat Sirisanthana
Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
description After responding to highly active antiretroviral therapy (HAART), HIV-infected children had a good response to hepatitis B immunization. However, there are limited data on the durability of antibody to hepatitis B surface antigen (anti-HBs) in these children. The primary objective of this study is to determine the prevalence of protective anti-HBs level 3 years after a 3-dose HBV revaccination among HIV-infected children with immune recovery (CD4 cell ≥15%) while on HAART. The secondary objective is to assess immunologic memory among children who had waning of anti-HBs. An anti-HBs level of ≥10mIU/mL was defined as a protective antibody level. Sixty-nine HIV-infected children who had history of a 3-dose HBV revaccination while receiving HAART were enrolled. The mean (SD) of CD4 cell and duration of HAART at time of revaccination was 27.2% (6.7) and 5.9 years (0.4), respectively. The proportion of children with protective anti-HBs level 3 years after the revaccination was 71.0% [95% CI, 58.8-81.3]. The geometric mean titer was 114(SD 5)IU/mL. By multivariate logistic analysis, the predictors for protective anti-HBs level 3 years after revaccination were CD4 cell count ≥500cells/mm3at the time of vaccination (p=0.04) and anti-HBs level ≥100IU/mL at 1 month after completion of the 3-dose vaccination (p<0.001). Anamnestic response after one booster dose was demonstrated among 14 of 17 children who had waning protective anti-HBs level (82.4% [95% CI, 62.2-102.6]). Our findings support the recommendation of giving a 3-dose HBV vaccination to HIV-infected children with immune recovery while receiving HAART. © 2011 Elsevier Ltd.
format Journal
author Mongkol Lao-araya
Thanyawee Puthanakit
Linda Aurpibul
Sineenart Taecharoenkul
Thira Sirisanthana
Virat Sirisanthana
author_facet Mongkol Lao-araya
Thanyawee Puthanakit
Linda Aurpibul
Sineenart Taecharoenkul
Thira Sirisanthana
Virat Sirisanthana
author_sort Mongkol Lao-araya
title Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
title_short Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
title_full Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
title_fullStr Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
title_full_unstemmed Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
title_sort prevalence of protective level of hepatitis b antibody 3 years after revaccination in hiv-infected children on antiretroviral therapy
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955646064&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/49720
_version_ 1681423460826349568